Pier 88 Investment Partners LLC Has $845,000 Holdings in Insulet Corporation $PODD

Pier 88 Investment Partners LLC trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 97.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,690 shares of the medical instruments supplier’s stock after selling 111,850 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Insulet were worth $845,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Larson Financial Group LLC raised its stake in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the 1st quarter worth about $26,000. SouthState Corp increased its holdings in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. acquired a new position in shares of Insulet during the second quarter valued at about $32,000. Finally, Golden State Wealth Management LLC lifted its stake in shares of Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the period.

Insulet Price Performance

Insulet stock opened at $319.82 on Friday. The business has a 50 day simple moving average of $325.06 and a 200 day simple moving average of $309.86. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market capitalization of $22.51 billion, a PE ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a one year low of $230.05 and a one year high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same period in the prior year, the company posted $1.08 earnings per share. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Jefferies Financial Group boosted their price target on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity Group boosted their price objective on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group cut their target price on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Finally, Truist Financial boosted their price target on shares of Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $370.76.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.